Successful treatment in allergic, autoimmune, and infectious diseases often requires altering the nature of a detrimental immune response mediated by a particular CD4+ T helper (Th) cell subset. While several factors contribute to the development of CD4+ Thi and Th2 cells, the requirements for switching an established response are not understood. Here we use infection with Leishmania major as a model to investigate those requirements. We report that treatment with interleukin 12 (IL-12), in combination with the antimony-based leishmanicidal drug Pentostam, induces healing in L. major-infected mice and that healing is associated with a switch from a Th2 to a Thl response. The data suggest that decreasing antigen levels may be required for to inhibit a Th2 response and enhance a Thi response.
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These observations are important for treatment of nonhealing forms of human leishmaniasis and also demonstrate that in a chronic infectious disease an inappropriate Th2 response can be switched to an effective Thi response.
The protozoan parasite Leishmania major causes a disease with a wide range of clinical manifestations. Experimental infections in mice mimic to a large extent the human disease. Strains of mice that are highly susceptible to L. major, such as BALB/c, develop poor cell-mediated immunity to the parasite and produce cytokines associated with T helper type 2 (Th2) responses, such as interleukin 4 (IL-4), IL-5, and IL-10, following infection (1, 2) . Similarly, enhanced levels of IL-4 and IL-10 have been reported in human patients with nonhealing forms of leishmaniasis (3) (4) (5) (6) . In contrast, resistant mouse strains such as C3H develop Thi responses, characterized by cell-mediated immunity and interferon 'y (IFN-.y) production. Various immunological manipulations can be used to render otherwise susceptible BALB/c mice resistant, including sublethal irradiation (7), B-cell depletion (8) , and treatment with anti-IL-4 (9, 10), anti-transforming growth factor ,B (TGF-13) (11) , anti-IL-2 (12), anti-CD4 (13), or, more recently, recombinant IL-12 (14, 15) . However, such treatments are effective only if administered at or near the time of parasite inoculation, suggesting that they influence the initial development of Thl cells from naive cells, rather than reverse an established Th2 response.
It has yet to be demonstrated in an infected BALB/c mouse that, once established, the nonprotective immune response can be sufficiently altered such that a protective Thi response predominates and healing of the lesion occurs. Accomplishment of this task will be of significance in the development of immunotherapies for controlling chronic infectious diseases such as leishmaniasis.
IL-12 is a cytokine that induces IFN-ny production and cytotoxic activity by natural killer and T cells (16, 17) and can initiate the differentiation of Thl cells from naive T cells
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. (18) (19) (20) (21) (22) . IL-12 enhances IFN-,y production by Thl clones (23) and promotes the proliferation of Thi but not Th2 cells (18) . However, in spite of its effects on established T-cell clones, IL-12 altered disease progression in leishmaniasis when administered at the time of infection, but not 1 week after infection (14, 15) . These data suggest that IL-12 is ineffective at promoting a Thi response in the presence of an ongoing Th2 response. We hypothesized that the failure of IL-12 to influence an ongoing Th2 response might relate to the high antigen levels associated with an established L. major infection, since antigen dose can influence the nature of an immune response (24) (25) (26) . Therefore, we investigated whether the immune response in L. major-infected BALB/c mice, and the outcome of infection, could be altered when IL-12 was administered to animals in which the parasite load was reduced.
Pentavalent antimony compounds such as Pentostam are commonly used for the treatment of human leishmaniasis, and we chose this compound to reduce the parasite burden in L. major-infected mice. While Pentostam is active against L. major, treatment of susceptible strains of mice, including BALB/c, rarely leads to a cure, since once treatment is terminated, the remaining parasite population almost invariably expands, leading to a fatal infection (27, 28) . These data suggest that successful treatment in leishmaniasis requires not only a reduction in parasite numbers but also the development of an effective cell-mediated immune response. Indeed, successful drug treatment in human visceral leishmaniasis is associated with the development of cell-mediated immunity (29 Immunological Assays. Popliteal lymph node and spleen cells (5 x 106 per ml) were cultured in Dulbecco's modified Eagle's medium (GIBCO) containing 10% fetal bovine serum, potassium penicillin G (100 units/ml), streptomycin sulfate (100 ,tg/ml), 25 mM Hepes, 2 mM L-glutamine, 50 p,M 2-mercaptoethanol, 1 mM sodium pyruvate at 37°C. After 72 hr, supernatants were harvested for cytokine analysis. Some cell cultures were stimulated in vitro with soluble leishmanial antigen (50 ,ug/ml) (32) . ELISAs were used to measure IFN--y and IL-4 (33) . Standards used in cytokine assays were recombinant IFN-,y (a gift from Genentech), and IL-4 (a gift from Robert Coffman, DNAX). IgE levels were measured by an isotype-specific ELISA using a monoclonal anti-mouse IgE (PharMingen) and a rat-anti-mouse IgE-horseradish peroxidase conjugate (Southern Biotechnology Associates) as a second antibody.
Reverse Transcription-PCR Analysis. Cytokine mRNA levels in tissues were analyzed essentially as described (34) . Primer and probe sequences for IFN--y and hypoxanthine phosphoribosyltransferase (HPRT) have been described (35) , and the following sequences were used to detect IL-4 cDNA: sense primer, 5'-ACGAGGTCACAGGAGAAGGGACGC-CATGCA-3'; antisense primer, 5'-GCTCTTTAGGCTTTC-CAGGAAGTC-3'; probe, 5'-CTCACAGCAACGAAGAA-CACCACAGAGAGT-3'. After initial denaturation at 94°C for 2 min, PCR consisted of 26 cycles (for HPRT and IFN-y) or 32 cycles (for IL-4) of 94°C for 15 sec, 54°C for 15 sec, 72°C for 1 min, followed by 72°C for 7 min. After agarose gel electrophoresis and Southern transfer, membranes were hybridized with the appropriate oligonucleotide probe labeled with the ECL system (Amersham). The method for determining fold increases in cytokine gene expression over normal cell levels has been described (34 (Fig. 1A) . Healing mice had lower numbers of tissue parasites compared with all other groups (Fig. 1B) . Additionally, of the four mice that healed, three had no detectable parasites in their spleens, indicating that the treatment inhibited metastasis of parasites from the primary lesion site.
In a second series of studies, we investigated whether the local administration of both IL-12 and Pentostam would increase the efficacy of treatment. In these experiments, IL-12 and Pentostam were administered together into the infected footpad, beginning 3 weeks after infection. The efficacy of the various therapies was initially assessed by quantifying the number of parasites in the footpad 1 week after treatment. Whereas footpads from PBS-treated mice had a parasite titer of >1012, those from mice treated with Pentostam alone had a titer of 106.4, demonstrating the effectiveness of the drug. Footpads from mice treated with IL-12 alone had a parasite titer of 1011-75 at this time, while those from mice treated with Pentostam plus IL-12 had a titer of 10144, indicating that treatment with these two agents had a synergistic effect on reducing the parasite burden.
Intralesional treatment with Pentostam delayed lesion development, as did treatment with IL-12 alone. However, neither treatment led to healing of the infection. In contrast, lesion growth was markedly suppressed when IL-12 and Pentostam were combined (Fig. 1C) . Four months after infection, 7 of 10 mice receiving this treatment had no visible lesion, while lesions on the remaining mice measured <0.5 mm at 16-22 weeks of infection. These healing mice had few parasites at the lesion site and no detectable parasites in the spleen, compared with the high levels of parasitization observed in all other groups (Fig. 1D ). In six experiments in which mice with established infections were treated with Pentostam (given i.m. or intralesionally) in combination with intralesional injection of IL-12, a 70% rate of healing (32 of 46 mice) was noted.
The ability of intralesional treatment with IL-12 and Pentostam to induce a healing response in L. major-infected BALB/c mice was associated with a switch in the dominant immune response observed in these animals. Prior to treatment, lymph node cells from infected mice produced high levels of IL-4 and low amounts of IFN--y ( Fig. 2A) . These results are consistent with previous studies demonstrating that by 2 weeks of infection, BALB/c mice have developed a dominant Th2 response (36) (37) (38) . Following successful therapy with IL-12 and Pentostam, however, the cytokine profile observed by cells in the lymph node had switched to a dominant Thi response ( Fig. 2A) . While we were unable to analyze lymph node cytokine production in the control mice after treatment, due to the extent of parasitism and necrosis within the lymph node, a comparison of responses in the spleen of healed (IL-12 plus Pentostam-treated) and nonhealed (IL-12 or Pentostam alone) animals confirmed our finding that a Thi response had developed in healing mice. Thus, following treatment, spleen cells from BALB/c mice treated intralesionally with IL-12 plus Pentostam produced more IFN-,y and less IL-4 than mice treated with either agent alone (Fig. 2 B and C) .
Reverse transcription-PCR analysis of cytokine mRNA levels confirmed that healing was associated with a dominant Thi response (Fig. 3) . Thus, Leishmania-reactive cells from healed mice contained more IFN-,y mRNA and.less IL-4 mRNA than those from control animals. Additionally, serum IgE levels, indicative of in vivo IL-4 production, were significantly lower in mice treated with IL-12 and Pentostam compared to those in mice treated with Pentostam or IL-12 alone (Fig. 2D) . Similar results were noted in the mice which healed following treatment with and Pentostam given i.m., described in Fig. 1A (data not shown) to a Thl-like cytokine production profile; rather, the mice apparently continued to preferentially expand the IL-4-producing cell population following treatment. These data agree with previous studies in which lesion development resumed following cessation of drug treatment in susceptible mice infected with L. major, despite the ability of the drug to reduce the parasite burden (27, 39 An association between high antigen loads and the development of Th2 responses has been previously described (24, 25) (45) . The mechanism by which antigen load influences Th cell subset dominance remains unclear. However, one factor may involve the capacity of high antigen levels to selectively tolerize CD4+ Thl cells (26 Fig. 1C) would predict that these animals should be resistant to reinfection. In fact, when challenged with 1 x 105 metacyclic promastigotes 15 weeks after treatment, IL-12 plus Pentostam-treated mice were immune to L. major infection, as evidenced by the absence of lesion development. Additionally, these cured mice exhibited a positive delayed-type hypersensitivity reaction in response to the challenge inoculum.
